Advertisement
Vanda has identified a series of pharmacogenetic markers during itsdevelopment of Fanapta(TM), and the company continues its pioneering work inthis area. Under the terms of the collaboration, LabCorp will be Vanda'sexclusive commercialization partner for tests for genetic markers of theFanapta(TM) program.
Advertisement
"Working with innovative companies like Vanda to commercialize predictivemedicine tests is a critical strategic focus for LabCorp," said Andrew J.Conrad, Ph.D., Chief Scientist and Global Head of Clinical Trials for LabCorp."This collaboration is an example of our commitment to the advancement ofpersonalized medicine and represents a successful translation of a researchbased assay into a valuable diagnostic test. This relationship is consistentwith our focus on companion diagnostics."
"We are pleased to be collaborating with LabCorp in this importanteffort," said Mihael H. Polymeropoulos, M.D., CEO of Vanda PharmaceuticalsInc. "LabCorp's diagnostic development expertise, world-class testingcapabilities, and national distribution network make them an ideal choice."
Schizophrenia is a chronic, severe, and disabling mental disorder thataffects more than two million Americans and approximately one percent of theworld's adult population. Patients suffering from schizophrenia exhibit arange of symptoms, including: positive symptoms, such as hallucinations anddelusions; negative symptoms, such as emotional withdrawal; and cognitivesymptoms associated with significant impairment in social and occupationalfunctioning.
About LabCorp(R)
Laboratory Corporation of America(R) Holdings, a S&P 500 company, is apioneer in commercializing new diagnostic technologies and the first in itsindustry to embrace genomic testing. With annual revenues of $4.1 billion in2007, over 26,000 employees nationwide, and more than 220,000 clients, LabCorpoffers clinical assays ranging from routine blood analyses to HIV and genomictesting. LabCorp combines its expertise in innovative clinical testingtechnology with its Centers of Excellence: The Center for Molecular Biologyand Pathology, National Genetics Institute, Inc., ViroMed Laboratories, Inc.,The Center for Esoteric Testing, DIANON Systems, Inc., US LABS, and Esoterixand its Colorado Coagulation, Endocrine Sciences, and Cytometry Associateslaboratories. LabCorp conducts clinical trial testing through its EsoterixClinical Trials Services division. LabCorp clients include physicians,government agencies, managed care organizations, hospitals, clinical labs, andpharmaceutical companies. To learn more about our organization, visit our Website at: www.labcorp.com .
Each of the above forward-looking statements is subject to change based onvarious important factors, including without limitation, competitive actionsin the marketplace and adverse actions of governmental and other third-partypayors. Actual results could differ materially from those suggested by theseforward-looking statements. Further information on potential factors thatcould affect LabCorp's financial results is included in the Company's Form 10-K for the year ended December 31, 2007, and subsequent
